J&J : DARZALEX FASPRO Quadruplet Regimen Improves MRD Negativity In Newly Diagnosed Multiple Myeloma
Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...
Targeted Oncology2d
Daratumumab With VRd Betters MRD Negativity in Transplant-Ineligible Myeloma
Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...
The American Journal of Managed Care2d
CEPHEUS: Sub-Q Daratumumab With VRd Improves MRD Negativity, PFS in Myeloma if Transplant Deferred
The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...
FiercePharma2d
After Sanofi's first-line myeloma nod, J&J strikes back with new tranche of Darzalex data
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
Johnson & Johnson: Cepheus Phase 3 Study Shows Improvement for Patients With Multiple Myeloma
Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...
The American Journal of Managed Care3d
CEPHEUS Outcomes Support Daratumumab Plus VRd as SOC in Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center, presented the results of the CEPHEUS trial and emphasized the positive impact ...
Targeted Oncology3d
Background and Findings of the CEPHEUS Trial in Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.